Teva Pharma Industries Ltd
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Teva Pharma Industries Ltd (TEVA). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| United States [Member] | – | – | $7.00B 46.9% | $7.73B 48.8% · +10.4% | $8.03B 48.6% · +3.9% | $9.19B 53.2% · +14.3% |
| Europe [Member] | $4.76B 28.6% | $4.89B 30.8% · +2.7% | $4.53B 30.3% · -7.4% | $4.84B 30.5% · +6.9% | $5.10B 30.8% · +5.5% | $5.04B 29.2% · -1.2% |
| International Markets [Member] | $2.15B 12.9% | $2.03B 12.8% · -5.7% | $2.35B 15.8% · +15.7% | $2.35B 14.8% · +0.0% | $2.46B 14.9% · +4.8% | $2.16B 12.5% · -12.2% |
| Other activities [Member] | $1.30B 7.8% | $1.15B 7.2% · -11.6% | $1.05B 7.0% · -9.2% | $926.0M 5.8% · -11.4% | $944.0M 5.7% · +1.9% | $870.0M 5.0% · -7.8% |
| North America [Member] | $8.45B 50.7% | $7.81B 49.2% · -7.6% | – | – | – | – |
| Corporate Segment [Member] | – | – | – | – | – | – |
| Other Segments [Member] | – | – | – | – | – | – |
| Segments and Other Activities [Member] | – | – | – | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| United States [Member] | – | – | $1.93B 27.6% | $2.39B 31.0% | $2.30B 28.6% | $3.36B 36.5% |
| Europe [Member] | $1.33B 28.0% | $1.49B 30.6% | $1.50B 33.1% | $1.48B 30.6% | $1.58B 30.9% | $1.30B 25.9% |
| International Markets [Member] | $474.0M 22.0% | $529.0M 26.0% | $538.0M 22.9% | $465.0M 19.8% | $440.0M 17.9% | $336.0M 15.5% |
| Other activities [Member] | – | – | – | – | – | – |
| North America [Member] | $2.42B 28.7% | $2.22B 28.5% | – | – | – | – |
| Corporate Segment [Member] | $4.23B | $4.25B | $3.97B | $4.34B | $4.31B | $5.00B |
| Other Segments [Member] | $163.0M | $154.0M | $172.0M | $24.0M | $18.0M | -$90.0M |
| Segments and Other Activities [Member] | $4.39B | $4.40B | – | – | – | – |
Large figure: segment operating income. Below it the margin, that is operating income measured against the revenue of the same segment.
Revenue by product line
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Sale of Goods [Member] | $14.35B 86.2% | $13.83B 87.1% · -3.7% | $12.77B 85.5% · -7.7% | $12.98B 81.9% · +1.7% | $14.05B 84.9% · +8.3% | $14.61B 84.6% · +4.0% |
| Distribution [Member] | $1.50B 9.0% | $1.39B 8.8% · -7.0% | $1.52B 10.2% · +9.3% | $1.62B 10.2% · +6.3% | $1.58B 9.5% · -2.4% | $1.55B 9.0% · -1.6% |
| Licensing Arrangements [Member] | $129.0M 0.8% | $160.0M 1.0% · +24.0% | $212.0M 1.4% · +32.5% | $681.0M 4.3% · +221.2% | $173.0M 1.0% · -74.6% | $678.0M 3.9% · +291.9% |
| Other [Member] | $680.0M 4.1% | $500.0M 3.1% · -26.5% | $428.0M 2.9% · -14.4% | $570.0M 3.6% · +33.2% | $745.0M 4.5% · +30.7% | $423.0M 2.5% · -43.2% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.